国药控股(01099)公布前三季度业绩 归母净利约53.07亿元 同比增长0.53%

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) reported a decline in revenue for the first nine months of 2025, while net profit showed a slight increase [1] Group 2 - The company's operating revenue for the first nine months was approximately 431.48 billion yuan, representing a year-on-year decrease of 2.47% [1] - The net profit attributable to the parent company's owners was about 5.31 billion yuan, reflecting a year-on-year growth of 0.53% [1] - The basic earnings per share were reported at 1.7 yuan [1]